Retinitis pigmentosa (RP) is the most common form of inherited vision loss and is characterized by degeneration of retinal photoreceptor cells and the retinal pigment epithelium (RPE). Mutations in pre-mRNA processing factor 31 (PRPF31) cause dominant RP via haploinsufficiency with incomplete penetrance. There is good evidence that the diverse severity of this disease is a result of differing levels of expression of the wild type allele among patients. Thus, we hypothesize that PRPF31-related RP will be amenable to treatment by adeno-associated virus (AAV)-mediated gene augmentation therapy. To test this hypothesis, we used induced pluripotent stem cells (iPSC) with mutations in PRPF31 and differentiated them into RPE cells. The mutant PRPF31 iPSC-RPE cells recapitulate the cellular phenotype associated with the PRPF31 pathology, including defective cell structure, diminished phagocytic function, defects in ciliogenesis, and compromised barrier function. Treatment of the mutant PRPF31 iPSC-RPE cells with AAV-PRPF31 restored normal phagocytosis and cilia formation, and partially restored structure and barrier function. These results provide proof-of concept that AAV-based gene therapy can be used to treat patients with PRPF31-related RP.
). AAV 2/2 and AAV2/Anc80 serotypes showed similar levels of long-term transduction, with the CASI promoter expressing higher levels of GFP versus CMV (2-way ANOVA. n=2 replicates/condition. p<0.0001) ( Figure 3B ). For the construct expressing the PRPF31 gene, we chose the serotype AAV2/Anc80 with the CASI promoter, due to the lower cell toxicity at a higher titer, higher transduction expression of GFP, and high reported in vivo transduction efficiency 29, 30 . A detailed AAV-PRPF31 vector map is provided in Figure S1 .
Functional defects in mutant iPSC-RPE PRPF31+/-cells can be rescued with AAV-mediated gene augmentation.

Phagocytic defects in iPSC-RPE PRPF31+/-can be rescued by AAV-mediated gene augmentation.
To test the use of gene augmentation therapy for PRPF31-associated disease, we treated patient derived and CRISPR-edited iPSC-RPE PRPF31 +/cells and control cells with AAV-PRPF31 12 . For these studies, differentiated iPSC-RPE cells at p2 were plated on matrigel-coated transwells and cultured in X-VIVO10 medium 27 . After four weeks, cells were confluent and pigmented, and were transduced with several doses of AAV2/Anc80 AAP.CASI.V5.PRPF31-mCHERRY.RBG (from now, AAV-PRPF31). Cells were cultured for an additional four weeks after AAV-PRPF31 treatment, and then PRPF31 expression and phagocytosis activity were evaluated. Immunostaining with antibodies for the V5 tag demonstrated stable transduction after 4 weeks and correct localization of the AAV-derived PRPF31 protein in the nucleus (Figure 3 ). The phagocytic function of the AAV-PRPF31 treated cells was assayed by challenging the cells with bovine FITC-labeled POS for 2 hours. Treatment with AAV-PRPF31 resulted in rescue of binding and internalization efficiencies in iPSC-RPE cells PRPF31 +/cells (2-way ANOVA, p=0.0322) ( Figure 4 ).
Interestingly, the phagocytic activity was enhanced in wild type iPSC-RPE PRPF31 +/+ cells treated with AAV-PRPF31 ( Figure 4) . Specifically, the capacity of binding POS increased by 2-fold when the cells were treated with 100,000 GC/cell (2-way ANOVA, p=0.0293) ( Figure 4B ), while the amount of internalized POS remained similar before and after AAV treatment ( Figure 4C ).
The effect of AAV-PRPF31 treatment on phagocytosis function was also evaluated in patient derived iPSC-RPE PRPF31 +/cells and corrected counterparts. The results of these studies demonstrated phagocytic activity was also restored in iPSC-RPE PRPF31 +/cells from a different genetic background in a dose dependent manner ( Figure 5 ).
Defects in cilia growth in iPSC-RPE PRPF31 +/can be rescued by AAV-mediated gene augmentation.
Among other defects, decreased cilia length was observed in patient derived PRPF31 +/-iPSC-RPE cells 12 . Immunostaining with antibodies for the cilia-specific marker ARL13B showed similar results in CRISPR-edited iPSC-RPE PRPF31 +/cells grown on transwells for 8 weeks, compared to wild type cells ( Figure 6 ). To test the ability of gene augmentation to correct this cilia defect, patient derived and CRISPR-edited iPSC-RPE PRPF31 +/cells were treated with AAV-PRPF31. Four weeks posttransduction with AAV-PRPF31, cilia length and incidence were restored to normal in both the patientderived and CRISPR-edited iPSC-RPE PRPF31 +/cells ( Figure 6 ) (2-way ANOVA, n=50cells/culture. p<0.0001). No effect was observed in wild type cells treated with the AAV-PRPF31 ( Figure 6 ).
Reduced barrier function in iPSC-RPE PRPF31 +/cultures is partially rescued by AAV-PRPF31.
The barrier function of the iPSC-RPE PRPF31 +/cell monolayer was compromised, as indicated by lower levels of TER ( Figure 2 ). To investigate the basis for this, we stained control and PRPF31 +/mutant iPSC-RPE with antibodies to collagen VI (COL VI) to assess extracellular matrix elaboration. As Disruption of the RPE monolayer in PRPF31 +/cultures was confirmed by transmission electron microscopy (TEM), in which cross-section images showed gaps between adjacent cells at the basal side while apical tight-junctions stayed intact ( Figure 7J , K), explaining the normal pattern of ZO-1 exhibited by iPSC-RPE mutant cells ( Figure 2 ). Additionally, stress vacuoles and shorter microvilli were observed in the mutant iPSC-PRPF31 +/cells. Treatment with AAV-PRPF31 results in fewer stress vacuoles and reduced gaps between the RPE cells ( Figure 7L ). Despite improved RPE cell morphology, TER values were not restored in iPSC-PRPF31 +/cultures after gene therapy treatment ( Figure S2 ), possibly because basal gaps between cells, although smaller, were still present after treatment ( Figure 7L ).
DISCUSSION
Autosomal dominant RP due to mutations in the PRPF31 gene is caused by haploinsufficiency 10,25 , providing an opportunity for treatment with gene-augmentation therapy. In this study, we modeled the cellular phenotype of the disease to test AAV-based PRPF31 gene augmentation therapy. Mutant iPSC-RPE PRPF31 +/cells grown on transwells for 8 weeks recapitulated the cellular phenotype associated with mutations in PRPF31, including abnormal structure, decreased phagocytic activity, defective ciliogenesis, and compromised barrier function. AAV-mediated PRPF31 gene augmentation therapy restored normal phagocytosis function and cilia length and partially restored barrier function in patient-derived and genome-edited iPSC-RPE PRPF31 +/cells. To the best of our knowledge, this is the first proof-of-concept that AAV-based gene therapy has the potential to be used for treatment of PRPF31-
The RPE monolayer is the primary cell type affected in PRPF31-related RP, and a number of cell and animal models have been developed that recapitulate the PRPF31-associated cellular phenotypes 6,9,12,25,31-33 . Consistent with prior reports, both the patient derived and genome edited PRPF31 mutant iPSC-RPE cells used in the current study demonstrated defective phagocytosis and cilia formation 12 . Our data suggest that mutations in PRPF31 affect both binding and internalization of POS, with a larger impact in POS binding; analogous to the defect described in mutant mouse RPE Prpf31 +/cells 6 .
Phagocytosis is a critical support function in continuously renewing light-sensitive outer segment portions, which is necessary for vision 34 . With diminished phagocytic activity, individual POS components are not degraded or recycled back to photoreceptors, eventually leading to photoreceptor loss 35 .
As expected by observations in RPE and optic cups derived from patients with mutations in Interestingly, the authors demonstrated that treatment with modulators of ciliogenesis can rescue the phagocytosis activity by the RPE cells 36 . Based on those results, we believe that the decreased phagocytosis activity observed in mutant iPSC-RPE PRPF31 +/cells may be secondary to the abnormal maturation of cilia and microvilli. In any case, the degeneration of the RPE occurs first, later leading to degeneration of the neural retina observed in patients 3, 36 . Thus, we postulate that the RPE is the best candidate tissue to be targeted by gene therapy. 
